[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Patrick Grace\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100653904","phase-4-ai-powered-hepatitis-c-single-encounter-test-and-treat-100653904",false,"NCT07793643","AI-Powered Hepatitis C Single-Encounter Test-and-Treat","Inclusion Criteria:\n\n* Age 22-65 years old, presenting to the Emergency Department (ED) who are undergoing antibody testing as part of universal screening\n* Patients to be discharged from the ED or ED Observational units\n\nExclusion Criteria:\n\n* Capacity to Consent\n* Emergency Severity Index (ESI) Level one (high acuity patients)\n* Known noninvasive serologic tests above proprietary cutoffs indicating cirrhosis (example - FibroSure, Enhanced Liver Fibrosis Test, etc.)\n* Known clinical evidence of cirrhosis (egliver nodularity and\u002For splenomegaly on imaging, platelet count \\\u003C150,000\u002Fm3, etc.)\n* Known prior liver biopsy showing cirrhosis\n\n  •Pregnancy\n* Known or suspected Hepatocellular carcinoma\n* Followed by hospice or transplant, have a life expectancy \\\u003C 1 year\n* Chronic Kidney Disease (CKD) or on dialysis\n* Allergy to study medications\n* Patients admitted to the hospital","ALL","22 Years","65 Years",{"count":19,"type":20},35,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This study will evaluate a single-visit approach to hepatitis C treatment in patients seen in the emergency department. Participants with hepatitis C will receive rapid testing and, if eligible, hepatitis C medication before leaving the emergency department. The study will also use a smart pillbox, an AI-powered virtual agent, and community health worker support to help participants take their medication as prescribed. Participants will have follow-up visits and testing to assess medication adherence and whether the hepatitis C infection is cured.",[26],"HEPATITIS C (HCV)","NOT_YET_RECRUITING","2026-08-26",{"date":30,"type":31},"2026-08-28","ACTUAL",{"date":33,"type":20},"2026-12-01",{"date":35,"type":20},"2028-09-01",{"name":37,"class":38},"Patrick Grace","OTHER",""]